Interactive Features

Test Your Knowledge

Quiz: Umbralisib Plus Ublituximab for Patients With TN, PT CLL

11/22/2021

True or false: the phase 3 UNITY-CLL study found umbralisib plus ublituximab has a tolerable safety profile and prolonged PFS compared to CIT in patients with both TN and PT CLL.

True or false: the phase 3...

11/22/2021

Oncology

Test Your Knowledge

Quiz: Is Orelabrutinib Effective for Patients With R/R CLL/SLL?

11/17/2021

True or false: A phase 2 study confirmed that orelabrutinib is effective for patients with R/R CLL/SLL.

True or false: A phase 2 study...

11/17/2021

Oncology

Test Your Knowledge

Quiz: Is Orelabrutinib Effective for Patients With R/R CLL/SLL?

11/17/2021

True or false: A phase 2 study confirmed that orelabrutinib is effective for patients with R/R CLL/SLL.

True or false: A phase 2 study...

11/17/2021

Oncology

Test Your Knowledge

Quiz: Do BCL-2 Inhibitors Achieve Durable Responses in CLL?

09/22/2021

True or false: Although patients with CLL achieve durable responses through novel inhibitor treatments, such as BTK inhibitors, BCL-2 inhibitors are nonapplicable.

True or false: Although patients...

09/22/2021

Oncology

Test Your Knowledge

Quiz: Do BCL-2 Inhibitors Achieve Durable Responses in CLL?

09/22/2021

True or false: Although patients with CLL achieve durable responses through novel inhibitor treatments, such as BTK inhibitors, BCL-2 inhibitors are nonapplicable.

True or false: Although patients...

09/22/2021

Oncology

Test Your Knowledge

Quiz: Does TBI Conditioning Lead to Improved Outcomes in CLL?

09/21/2021

True or false: Internal institutional data from Memorial Sloan Kettering Cancer Center show that in patients with CLL, TBI conditioning resulted in poor outcomes of PFS and OS.

True or false: Internal...

09/21/2021

Oncology

Quiz

Quiz: What is The Synergistic Profile of This Combo Regimen for R/R CLL?

08/20/2021

True or false: The synergistic profile of ibrutinib and venetoclax for the use of a MRD-driven strategy is defined as follows: venetoclax is a BTK inhibitor that acts on the lymphoproliferative compartment and ibrutinib is a BCL2 inhibitor...

True or false: The synergistic...

08/20/2021

Oncology

Test Your Knowledge

Quiz: Which Type of Leukemia is the Most Prevalent in the United States?

08/18/2021

Which type of leukemia is the most common in adult patients from the US?

Which type of leukemia is the...

08/18/2021

Oncology

Test Your Knowledge

Quiz: Is Venetoclax Plus Obinutuzumab Effective in Previously Untreated CLL?

11/17/2020

True or False: Venetoclax plus obinutuzumab was found to be a more effective treatment than chlorambucil plus obinutuzumab in previously untreated chronic lymphocytic leukemia.

True or False: Venetoclax plus...

11/17/2020

Oncology

Test Your Knowledge

Quiz: What Does BTK Induction Activate?

11/03/2020

True or False: When Bruton's tyrosine kinase is inducted, it activates phospholipase C and calcium mobilization.

True or False: When Bruton's...

11/03/2020

Oncology

Recent News

News

Osimertinib Lacks Activity in Neoadjuvant Setting for Early-Stage Non-Small Cell Lung Cancer With EGFR Mutation

08/08/2024

Stephanie Holland ;

Results from a phase 2 study demonstrated that neoadjuvant osimertinib did not improve the major pathological response rate among patients with early-stage non-small cell lung cancer harboring an EGFR mutation.

Results from a phase 2 study...

08/08/2024

Oncology

FDA Approval

FDA Approves Denileukin Diftitox for Patients With R/R Cutaneous T-Cell Lymphoma

08/08/2024

Amber Denham ;

The US Food and Drug Administration approved novel immunotherapy denileukin diftitox-cxdl for the treatment of patients with relapsed/refractory cutaneous T-cell lymphoma after at least 1 prior systemic therapy.

The US Food and Drug...

08/08/2024

Oncology

News

Tailored Dose-Dense Chemotherapy Improved Survival Outcomes Among Patients With High-Risk Early Breast Cancer

08/07/2024

Stephanie Holland ;

According to results from the phase 3 PANTHER trial, tailored and dose-dense chemotherapy in the adjuvant setting improved survival outcomes compared to standard chemotherapy among patients with high-risk early breast cancer.

According to results from the...

08/07/2024

Oncology

News

Frontline Treatment Management for Patients With FL Reduces Risk of High-Grade Transformation to DLBCL

08/07/2024

Amber Denham ;

A recent study demonstrated that frontline treatment management reduced the risk of high-grade transformation to diffuse large B-cell lymphoma among patients with follicular lymphoma, but not among patients with marginal zone lymphoma.

A recent study demonstrated that...

08/07/2024

Oncology

News

Optimal Sotorasib Dose for Patients With KRAS G12C-Mutated Advanced Non-Small Cell Lung Cancer

08/07/2024

Stephanie Holland ;

Results from a phase 2 study found that 960 mg of sotorasib is preferable to 240 mg among patients with previously treated KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer.

Results from a phase 2 study...

08/07/2024

Oncology

FDA Approval

FDA Approves Vorasidenib for Patients With IDH1/IDH2-Mutated Grade 2 Astrocytoma or Oligodendroglioma

08/06/2024

Stephanie Holland ;

Based on results from the INDIGO trial, the FDA has approved vorasidenib for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation following surgery.

Based on results from the INDIGO...

08/06/2024

Oncology

FDA Approval

FDA Approves Afamitresgene Autoleucel for Certain Unresectable or Metastatic Synovial Sarcoma

08/02/2024

Allison Casey ;

On August 2, 2024, the US Food and Drug Administration (FDA) granted accelerated approval to afamitresgene autoleucel for the treatment of adult patients with certain unresectable or metastatic synovial sarcomas who had received prior...

On August 2, 2024, the US Food...

08/02/2024

Oncology

FDA Approval

FDA Approves Dostarlimab Plus Chemotherapy for Patients With Primary Advanced or Recurrent Endometrial Cancer

08/01/2024

Allison Casey ;

The FDA approved dostarlimab plus carboplatin and paclitaxel, followed by single-agent dostarlimab for patients with primary advanced or recurrent endometrial cancer.

The FDA approved dostarlimab...

08/01/2024

Oncology

News

Iadademstat and Azacitidine Combination Therapy Demonstrates Manageable Safety, Promising Efficacy for Patients With Newly Diagnosed AML

08/01/2024

Amber Denham ;

The first-line combination of iadademstat and azacitidine demonstrates a manageable safety profile and promising results among patients with acute myeloid leukemia, according to phase 2 results from the ALICE trial.

The first-line combination of...

08/01/2024

Oncology

News

Effect of Food on Selumetinib Dosing for Adolescent Patients With Neurofibromatosis Type 1 With Plexiform Neurofibromas

08/01/2024

Allison Casey ;

In the phase 1 trial, the addition of a low-fat meal with doses of selumetinib did not significantly impact selumetinib exposure or gastrointestinal toxicities among adolescent patients with neurofibromatosis type 1 with plexiform...

In the phase 1 trial, the...

08/01/2024

Oncology